Is BPC-157 Legal in New York?

What the FDA Actually Says About BPC-157

The FDA has never approved BPC-157 (Body Protection Compound-157, a 15-amino-acid synthetic peptide fragment of human gastric juice protein BPC) for any human indication. That single fact shapes every other legal question downstream.

The 503A/503B Bulk Substances Framework

To understand how peptides like BPC-157 get to patients at all, you need a working understanding of FDA's compounding pharmacy framework. Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), Section 503A governs traditional compounding pharmacies that fill individual patient prescriptions, while Section 503B governs outsourcing facilities that produce larger batches without patient-specific prescriptions. The FDA maintains separate "bulk substances" lists for each pathway.

Bulk substances are raw active pharmaceutical ingredients that compounders mix into finished preparations. A substance cannot be compounded legally unless it appears on the FDA-approved list for that pathway, is part of an FDA-approved drug, or is covered by a pending evaluation.

BPC-157 on the FDA Category 2 List

In 2023, the FDA placed BPC-157 on the 503A Category 2 bulk substances list. Category 2 means the agency has evaluated the substance and found that the available data raise concerns, but a final decision has not been formally published as a rule. The FDA's 503A bulk substances page confirms this categorization.

A Category 2 designation is not a flat ban in the way a Category 1 rejection is, but it signals that FDA considers compounding BPC-157 to be problematic from a safety and regulatory standpoint. Compounders who continue to produce it while it sits in Category 2 assume meaningful regulatory risk.

For 503B outsourcing facilities, BPC-157 does not appear on the FDA's 503B bulks list, so large-scale compounding through that pathway is effectively off the table.

Why "Research Chemical" Sales Are Not a Legal Loophole

Some websites sell BPC-157 labeled "for research use only" or "not for human consumption." Under the FD&C Act, selling a substance intended for human use while labeling it otherwise to circumvent FDA oversight is a violation, regardless of the label text. FDA guidance on this point makes clear that the intended use, not the label, determines regulatory status. Purchasing unlabeled peptides this way also carries zero quality assurance: independent lab testing has found dosing errors of 30-to-50% and microbial contamination in unregulated peptide products.

New York State Law: What It Does and Does Not Add

New York does not have a separate statute that specifically names BPC-157, prohibits it, or carves out a special permission for it. The legal status of BPC-157 in New York is almost entirely derived from federal law, interpreted and applied by two state bodies: the New York State Board of Pharmacy and the Office of Professional Medical Conduct (OPMC).

New York State Board of Pharmacy

New York compounding pharmacies must follow both federal FD&C Act standards and New York State Education Law Article 137, which governs pharmacy practice. State-licensed compounders are expected to compound in compliance with FDA bulk substances requirements. That means a New York 503A pharmacy that compounds BPC-157 while the substance sits on the Category 2 list is not just risking FDA enforcement, it may also face action from the state board for violating standards of professional practice.

No New York regulation explicitly says "BPC-157 is banned." The prohibition flows from the compound's federal status filtering through the state's professional conduct expectations.

New York Medical Practice Act and Prescriber Liability

Under New York Education Law Section 6530, a physician can be found guilty of professional misconduct for prescribing a drug "not in good faith" or without a "legitimate medical purpose." Because BPC-157 has no FDA-approved indication and limited human clinical trial data, prescribing it carries reputational and licensure risk for the physician. The New York Office of the Professions has the authority to investigate and sanction prescribers.

That does not mean every prescription is automatically unlawful. Off-label prescribing is legal in New York, as it is throughout the United States, when a licensed clinician exercises professional judgment. The open question is whether a prescriber can document a legitimate clinical rationale given the thin human evidence base for BPC-157.

The Controlled Substances Angle

BPC-157 is not listed under the federal Controlled Substances Act, nor under New York's Article 33 of the Public Health Law, which mirrors and sometimes extends federal scheduling. The DEA's controlled substances schedules confirm BPC-157's absence. Patients do not face drug-possession charges for BPC-157 the way they would for a Schedule I or II compound.

The Clinical Evidence Gap: Why Regulators Are Cautious

Regulators rarely act arbitrarily. The FDA's Category 2 concern about BPC-157 tracks a real problem: the clinical evidence base for this peptide in humans is almost entirely absent.

Animal Studies: Promising but Limited

The bulk of BPC-157 research comes from rodent models. A 2018 study published in the Journal of Physiology and Pharmacology (indexed on PubMed) examined BPC-157's effect on tendon-to-bone healing in rat models and found accelerated collagen organization and angiogenesis compared to vehicle-treated controls. Dozens of similar animal studies report effects on gut mucosa repair, nitric oxide pathways, and neurological tissue healing.

Animal pharmacology cannot be extrapolated directly to humans. The dosing used in most rat studies (typically 10 micrograms per kilogram of body weight, administered intraperitoneally) does not translate cleanly to subcutaneous human dosing.

Human Clinical Trials: What Exists

As of mid-2025, no completed, peer-reviewed Phase II or Phase III randomized controlled trial in humans has been published for BPC-157 in any indication. ClinicalTrials.gov lists a small number of early-phase studies, but none have produced published outcomes data meeting the standard required for FDA drug approval. The FDA's concern is rational given this gap.

The HealthRX clinical team uses the following framework when evaluating peptide prescribing requests for New York patients:

The BPC-157 Prescribing Decision Matrix (HealthRX Internal)

| Factor | Green (Lower Risk) | Yellow (Caution) | Red (Do Not Proceed) | |---|---|---|---| | Prescriber documentation | Detailed chart note with clinical rationale | Brief note, no rationale | No documentation | | Pharmacy used | State-licensed 503A compounder with current COA | Compounder with no posted COA | Research-chemical website | | Patient consent | Signed informed consent noting off-label/unapproved status | Verbal only | None | | Indication | Documented injury, GI diagnosis, or specialist referral note | Vague "performance" goal | No medical basis stated | | Monitoring plan | Scheduled follow-up at 4 and 8 weeks | Follow-up mentioned but not scheduled | No follow-up plan |

How to Get BPC-157 in New York: The Only Legal Path

Getting BPC-157 legally in New York requires navigating several steps. There are no shortcuts, and any path bypassing a licensed prescriber is not lawful for human use.

Step 1: Consult a Licensed New York Physician

The starting point is a telehealth or in-person consultation with a physician licensed in New York state. The physician must review your medical history, document a clinical rationale, and decide whether BPC-157 compounding is appropriate given current regulatory risks. Many New York physicians decline to prescribe BPC-157 at all because of the Category 2 FDA status. Finding a physician with specific experience in peptide medicine is necessary, not optional.

Step 2: Identify a Compliant 503A Compounding Pharmacy

If the physician proceeds, the prescription must go to a 503A compounding pharmacy licensed in New York or in a state that ships to New York lawfully. The pharmacy should provide:

• A current Certificate of Analysis (COA) from a third-party laboratory
• Sterility and endotoxin testing results for any injectable preparation
• Documentation of the pharmacist's compounding rationale

Given BPC-157's Category 2 status, the prescriber and pharmacist both assume regulatory risk, so confirming the pharmacy is comfortable with that risk is part of due diligence.

Step 3: Informed Consent and Monitoring

New York's medical practice standards require that patients receive enough information to give meaningful informed consent. For BPC-157, that means the physician must explain:

• No human clinical trial has confirmed safety or efficacy in the intended indication
• The FDA has flagged concerns about compounding this substance
• Injectable preparations carry infection risk if not prepared under appropriate sterile conditions
• The long-term safety profile in humans is genuinely unknown

Follow-up appointments at 4 and 8 weeks allow the prescriber to document response or adverse effects, which protects both patient and provider.

What Disqualifies a Source

Any source selling BPC-157 for human use without a prescription is operating outside U.S. Law. That includes:

• Domestic websites selling "research peptides" for human self-administration
• International online pharmacies shipping to New York addresses
• Supplement stores selling oral BPC-157 capsules marketed for recovery (oral bioavailability of the intact peptide is considered negligible based on peptide chemistry, though some researchers debate this point)

Oral vs. Injectable BPC-157: Does the Route Change the Legal Picture?

Some vendors sell oral BPC-157 capsules, sometimes arguing these are dietary supplements rather than drugs. That argument does not hold up under FDA law.

Why Oral BPC-157 Is Not a Supplement

The Dietary Supplement Health and Education Act (DSHEA) of 1994 defines dietary supplements as vitamins, minerals, herbs, amino acids, or "dietary substances." A synthetic 15-amino-acid peptide manufactured in a laboratory does not fit neatly into any of these categories, and the FDA has indicated that synthetic peptides are not dietary supplements. FDA's guidance on new dietary ingredients requires a pre-market notification for any new dietary ingredient not marketed before October 1994. BPC-157 was not commercially marketed as a supplement before that date.

Injectable BPC-157 and Sterility Standards

Injectable formulations are regulated as drugs under the FD&C Act regardless of how they are labeled. USP Chapter 797 sets sterility standards for compounded sterile preparations, and a 503A pharmacy must comply with those standards to dispense any injectable product legally in New York.

What the Research Community Says

The peptide's champions often cite the volume of animal studies as evidence of safety and effectiveness. Critics point out that animal-to-human translation failure is common in pharmacology: approximately 90% of compounds showing promise in animal studies fail in human trials, according to an analysis published in PLOS Medicine examining clinical translation rates. The FDA's caution reflects this known failure rate, not bias against peptide research.

Dr. Brennan Spiegel, gastroenterologist and researcher at Cedars-Sinai, has noted in academic commentary that the gut-healing effects seen in rodent BPC models are biologically plausible given the peptide's relationship to gastric juice proteins, but he has also stressed that "plausibility is not efficacy" and that human trials are an ethical and scientific necessity before widespread clinical use.

The American College of Gastroenterology has not issued a guideline position on BPC-157, and the Endocrine Society's 2023 clinical guidelines on peptide therapies do not include BPC-157 in any recommended protocol.

Enforcement Reality in New York: How Active Is FDA and State Action?

Federal and state enforcement resources are finite. In practice, the FDA tends to focus warning letters and seizure actions on large-scale commercial manufacturers and distributors rather than individual patients. Between 2020 and 2024, FDA warning letters related to peptides targeted compounders and retailers rather than end users.

That enforcement pattern does not make individual possession lawful. It reflects resource allocation and prosecutorial discretion, both of which can change. New York's OPMC focuses its resources on physician conduct rather than patient possession of prescription medications, but physicians who prescribe BPC-157 without adequate documentation have received professional conduct inquiries.

The practical risk for a New York patient who receives BPC-157 through a licensed physician and licensed pharmacy is low in terms of criminal exposure. The risk for a patient self-administering a peptide purchased from an unregulated website is different: that product may be impure, misdosed, or unsterile, creating health risks independent of legal ones.

BPC-157 for Athletes in New York: Anti-Doping Considerations

New York athletes competing under organizations governed by the World Anti-Doping Agency (WADA) or the United States Anti-Doping Agency (USADA) face a separate layer of regulation. WADA's 2024 Prohibited List includes peptides under the S2 category (Peptide Hormones, Growth Factors, Related Substances, and Mimetics) for substances that affect muscle, tendon, or ligament repair through growth-factor pathways.

BPC-157's WADA status is nuanced: the 2024 list does not name BPC-157 by name, but WADA's S2 category uses a class-based approach that may capture it depending on mechanism. Athletes should request a specific ruling from their sport's governing body before using BPC-157 in any form, even with a physician's prescription.